Seqens is an integrated global player in pharmaceutical synthesis and specialty ingredients with a broad range of products, services and technologies. The group offers its customers contract manufacturing services for the pharmaceutical and specialty markets as well as a broad portfolio of active ingredients, pharmaceutical intermediates and specialty products.
Seqens operates 24 production sites and 3 R&D centers in Europe, North America and Asia and employs 3,200 people. More than 300 scientists, engineers and experts develop tailor-made solutions for our customers and ensure that products are successfully put into production.
Seqens, science at the heart of its activities.
The name Seqens refers to our synthesis activities and evokes the idea of sequencing when we build our molecules and cross-reference our skills and technologies.
In the pharmaceutical industry, Seqens supports its customers in the development, industrialization and manufacturing of drug substances, from the preclinical phase to marketing, and offers a broad portfolio of active ingredients and proprietary products.
Seqens also develops customized solutions and ingredients for the most demanding industries such as health, electronics, cosmetics, food and the environment.
Seqens , The Continuum of Progress
"With Seqens, we intend to be a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our ambition is to develop and produce the most complex molecules thanks to our recognized expertise and a broad continuum of technologies that is unique on the market. I am proud of what our 3,200 employees have accomplished so far. Today, we are opening a new page in the history of our group," said Pierre Luzeau, President of Seqens.
About Novacap
The Novacap Group's subsidiaries - Novacarb, Novacyl, Novapex, Novacid, Novabay, Uetikon, H2B, ID Bio, PCAS, Chemoxy and PCI Synthesis - are distinguished by their leading positions in various markets, including cosmetics and fragrances, food and feed, detergents, environment and electronics.
The legal entities of Novacap's subsidiaries - Novacarb, Novacyl, Novapex, Novacid, Novabay, Uetikon, H2B, ID Bio, PCAS, Chemoxy and PCI Synthesis - will remain in place.
